{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T04:21:01Z","timestamp":1787458861921,"version":"build-2736575974"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04314-8","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:59:28Z","timestamp":1774684768000},"page":"3708-3729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The logarithmic phase as a therapeutic direction: evaluating pharmacological strategies against cancer progression"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9006-1397","authenticated-orcid":false,"given":"Sushanta Kumar","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saptarshi","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabitri","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rintu","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"3","key":"4314_CR1","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1016\/S2214-109X(25)00494-2","volume":"14","author":"O Langselius","year":"2026","unstructured":"Langselius O, Rumgay H, Vignat J, Charvat H, Rutherford MJ, Mafra A, et al. Avoidable deaths through the primary prevention, early detection, and curative treatment of cancer worldwide: a population-based study. Lancet Glob Health. 2026;14(3):e356\u201366. https:\/\/doi.org\/10.1016\/S2214-109X(25)00494-2.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"4314_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5114\/wo.2019.84112","volume":"23","author":"B Farhood","year":"2019","unstructured":"Farhood B, Raei B, Malekzadeh R, Shirvani M, Najafi M, Mortezazadeh T. A review of incidence and mortality of colorectal, lung, liver, thyroid, and bladder cancers in Iran and compared to other countries. Wspolczesna Onkol. 2019;23(1):7\u201315. https:\/\/doi.org\/10.5114\/wo.2019.84112.","journal-title":"Wspolczesna Onkol"},{"key":"4314_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3159-y","volume":"17","author":"MM Gonz\u00e1lez","year":"2017","unstructured":"Gonz\u00e1lez MM, Joa JA, Cabrales LE, Pupo AE, Schneider B, Kondakci S, et al. Is cancer a pure growth curve or does it follow a kinetics of dynamical structural transformation? BMC Cancer. 2017;17:174. https:\/\/doi.org\/10.1186\/s12885-017-3159-y.","journal-title":"BMC Cancer"},{"issue":"8","key":"4314_CR4","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","volume":"38","author":"A Richters","year":"2020","unstructured":"Richters A, Aben K, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895\u2013904. https:\/\/doi.org\/10.1007\/s00345-019-02984-4.","journal-title":"World J Urol"},{"issue":"2","key":"4314_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ags3.12434","volume":"5","author":"R Matsuyama","year":"2021","unstructured":"Matsuyama R, Yabusita Y, Homma Y, Kumamoto T, Endo I. Essential updates 2019\/2020: surgical treatment of gallbladder cancer. Ann Gastroenterol Surg. 2021;5(2):152\u201361. https:\/\/doi.org\/10.1002\/ags3.12434.","journal-title":"Ann Gastroenterol Surg"},{"key":"4314_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.17.00080","volume":"2","author":"CA Rayfield","year":"2018","unstructured":"Rayfield CA, Grady F, De Leon G, Rockne R, Carrasco E, Jackson P, et al. Distinct phenotypic clusters of glioblastoma growth and response kinetics predict survival. JCO Clin Cancer Inform. 2018;2:1\u201314. https:\/\/doi.org\/10.1200\/CCI.17.00080.","journal-title":"JCO Clin Cancer Inform"},{"issue":"3","key":"4314_CR7","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/GRF.0000000000000789","volume":"66","author":"C Cohen","year":"2023","unstructured":"Cohen C, Clarke M. Anal cancer and anal cancer screening. Clin Obstet Gynecol. 2023;66(3):516\u201333. https:\/\/doi.org\/10.1097\/GRF.0000000000000789.","journal-title":"Clin Obstet Gynecol"},{"issue":"11","key":"4314_CR8","doi-asserted-by":"publisher","first-page":"10049","DOI":"10.1021\/acsnano.6b04695","volume":"10","author":"Z Chen","year":"2016","unstructured":"Chen Z, Zhao P, Luo Z, Zheng M, Tian H, Gong P, et al. Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano. 2016;10(11):10049\u201357. https:\/\/doi.org\/10.1021\/acsnano.6b04695.","journal-title":"ACS Nano"},{"issue":"8","key":"4314_CR9","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1158\/2767-9764.CRC-22-0032","volume":"2","author":"A Nasim","year":"2022","unstructured":"Nasim A, Yates J, Derks G, Dunlop C. A spatially resolved mechanistic growth law for cancer drug development predicting tumor growing fractions. Cancer Res Commun. 2022;2(8):754\u201361. https:\/\/doi.org\/10.1158\/2767-9764.CRC-22-0032.","journal-title":"Cancer Res Commun"},{"issue":"3","key":"4314_CR10","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ijrobp.2025.09.034","volume":"124","author":"KA Luddy","year":"2026","unstructured":"Luddy KA, West J, Robertson-Tessi M, Desai B, Ojeda A, Newman H, et al. Evolutionary double-bind treatment using radiation therapy and natural killer cell-based immunotherapy in prostate cancer. Int J Radiat Oncol Biol Phys. 2026;124(3):702\u201316. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.09.034.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4314_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4682-3-10","volume":"3","author":"S Cooper","year":"2006","unstructured":"Cooper S. Distinguishing between linear and exponential cell growth during the division cycle: single-cell studies, cell-culture studies, and the object of cell-cycle research. Theor Biol Med Model. 2006;3:10. https:\/\/doi.org\/10.1186\/1742-4682-3-10.","journal-title":"Theor Biol Med Model"},{"issue":"11","key":"4314_CR12","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202400769R","volume":"38","author":"S Cavalu","year":"2024","unstructured":"Cavalu S, Abdelhamid AM, Saber S, Elmorsy EA, Hamad RS, Abdel-Reheim MA, et al. Cell cycle machinery in oncology: a comprehensive review of therapeutic targets. FASEB J. 2024;38(11):e23734. https:\/\/doi.org\/10.1096\/fj.202400769R.","journal-title":"FASEB J"},{"issue":"1","key":"4314_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.gendis.2022.11.025","volume":"11","author":"EH Maleki","year":"2023","unstructured":"Maleki EH, Bahrami AR, Matin MM. Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance. Genes Dis. 2023;11(1):189\u2013204. https:\/\/doi.org\/10.1016\/j.gendis.2022.11.025.","journal-title":"Genes Dis"},{"key":"4314_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1459057","volume":"15","author":"G Song","year":"2024","unstructured":"Song G, Liu J, Tang X, Zhong J, Zeng Y, Zhang X, et al. Cell cycle checkpoint revolution: targeted therapies in the fight against malignant tumors. Front Pharmacol. 2024;15:1459057. https:\/\/doi.org\/10.3389\/fphar.2024.1459057.","journal-title":"Front Pharmacol"},{"key":"4314_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1146\/annurev.pharmtox.48.113006.094626","volume":"50","author":"F L\u00e9vi","year":"2010","unstructured":"L\u00e9vi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2010;50:377\u2013421. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094626.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"4314_CR16","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1158\/0008-5472.CAN-06-3822","volume":"67","author":"E Mehrara","year":"2007","unstructured":"Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res. 2007;67(8):3970\u20135. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3822.","journal-title":"Cancer Res"},{"issue":"2","key":"4314_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1051\/m2an\/2012031","volume":"47","author":"A Lorz","year":"2013","unstructured":"Lorz A, Lorenzi T, Hochberg ME, Clairambault J, Perthame B. Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies. ESAIM: Mathematical Modelling and Numerical Analysis. 2013;47(2):377\u201399. https:\/\/doi.org\/10.1051\/m2an\/2012031.","journal-title":"ESAIM: Mathematical Modelling and Numerical Analysis"},{"key":"4314_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2014.02.003","volume":"30","author":"GG Powathil","year":"2015","unstructured":"Powathil GG, Swat M, Chaplain MA. Systems oncology: towards patient-specific treatment regimes informed by multiscale mathematical modelling. Semin Cancer Biol. 2015;30:13\u201320. https:\/\/doi.org\/10.1016\/j.semcancer.2014.02.003.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"4314_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-024-00397-7","volume":"10","author":"C Ma","year":"2024","unstructured":"Ma C, Gurkan-Cavusoglu E. A comprehensive review of computational cell cycle models in guiding cancer treatment strategies. NPJ Syst Biol Appl. 2024;10(1):71. https:\/\/doi.org\/10.1038\/s41540-024-00397-7.","journal-title":"NPJ Syst Biol Appl"},{"key":"4314_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101018","volume":"72","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chen Y, Zhang J, Yang Y, Fleishman JS, Wang Y, et al. Cuproptosis: a novel therapeutic target for overcoming cancer drug resistance. Drug Resist Updates. 2024;72:101018. https:\/\/doi.org\/10.1016\/j.drup.2023.101018.","journal-title":"Drug Resist Updates"},{"issue":"9","key":"4314_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/mi10090580","volume":"10","author":"A Taghibakhshi","year":"2019","unstructured":"Taghibakhshi A, Barisam M, Saidi MS, Navid K, Nguyen N-T. Three-dimensional modeling of avascular tumor growth in both static and dynamic culture platforms. Micromachines (Basel). 2019;10(9):580. https:\/\/doi.org\/10.3390\/mi10090580.","journal-title":"Micromachines (Basel)"},{"issue":"8","key":"4314_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003800","volume":"10","author":"S Benzekry","year":"2014","unstructured":"Benzekry S, Lamont C, Beheshti A, Tracz A, Ebos JML, Hlatky L, et al. Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth. PLoS Comput Biol. 2014;10(8):e1003800. https:\/\/doi.org\/10.1371\/journal.pcbi.1003800.","journal-title":"PLoS Comput Biol"},{"issue":"18","key":"4314_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241813996","volume":"24","author":"G Pet\u0151v\u00e1ri","year":"2023","unstructured":"Pet\u0151v\u00e1ri G, T\u00f3th G, Turi\u00e1k L, Kiss AL, P\u00e1l\u00f3czi K, Sebesty\u00e9n A, et al. Dynamic interplay in tumor ecosystems: Communication between hepatoma cells and fibroblasts. Int J Mol Sci. 2023;24(18):13996. https:\/\/doi.org\/10.3390\/ijms241813996.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4314_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611\u201329. https:\/\/doi.org\/10.1038\/nrclinonc.2017.44.","journal-title":"Nat Rev Clin Oncol"},{"key":"4314_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fonc.2013.00051","volume":"3","author":"DI Wallace","year":"2013","unstructured":"Wallace DI, Guo X. Properties of tumor spheroid growth exhibited by simple mathematical models. Front Oncol. 2013;3:51. https:\/\/doi.org\/10.3389\/fonc.2013.00051.","journal-title":"Front Oncol"},{"issue":"3","key":"4314_CR26","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00026.2006","volume":"87","author":"N Heldring","year":"2007","unstructured":"Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007;87(3):905\u201331. https:\/\/doi.org\/10.1152\/physrev.00026.2006.","journal-title":"Physiol Rev"},{"issue":"3","key":"4314_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1056\/NEJMra050776","volume":"354","author":"JD Yager","year":"2006","unstructured":"Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354(3):270\u201382. https:\/\/doi.org\/10.1056\/NEJMra050776.","journal-title":"N Engl J Med"},{"issue":"9","key":"4314_CR28","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"A Loktev","year":"2018","unstructured":"Loktev A, Lindner T, Mier W, Debus J, Altmann A, J\u00e4ger D, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59(9):1423\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.210435.","journal-title":"J Nucl Med"},{"issue":"8","key":"4314_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000399","volume":"17","author":"KE Johnson","year":"2019","unstructured":"Johnson KE, Howard G, Mo W, Strasser MK, Lima EABF, Huang S, et al. Cancer cell population growth kinetics at low densities deviate from the exponential growth model and suggest an Allee effect. PLoS Biol. 2019;17(8):e3000399. https:\/\/doi.org\/10.1371\/journal.pbio.3000399.","journal-title":"PLoS Biol"},{"issue":"10","key":"4314_CR30","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.3390\/cancers12102744","volume":"12","author":"SP Langdon","year":"2020","unstructured":"Langdon SP. Estrogen receptor signaling in cancer. Cancers (Basel). 2020;12(10):2744. https:\/\/doi.org\/10.3390\/cancers12102744.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4314_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molmed.2009.11.005","volume":"16","author":"X Liu","year":"2010","unstructured":"Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010;16(1):37\u201345. https:\/\/doi.org\/10.1016\/j.molmed.2009.11.005.","journal-title":"Trends Mol Med"},{"issue":"1","key":"4314_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22\u201335. https:\/\/doi.org\/10.1016\/j.cell.2012.03.003.","journal-title":"Cell"},{"issue":"6127","key":"4314_CR33","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546\u201358. https:\/\/doi.org\/10.1126\/science.1235122.","journal-title":"Science"},{"issue":"6","key":"4314_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"15","author":"N Ferrara","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385\u2013403. https:\/\/doi.org\/10.1038\/nrd.2015.17.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"4314_CR35","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"11","key":"4314_CR36","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337. https:\/\/doi.org\/10.1038\/nm.3394.","journal-title":"Nat Med"},{"issue":"7637","key":"4314_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nature"},{"issue":"1","key":"4314_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01045-x","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Zhang J, Li A, Niu M, Yan Y, Jiao Y, et al. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1. J Hematol Oncol. 2021;14(1):27. https:\/\/doi.org\/10.1186\/s13045-021-01045-x.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4314_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41467-024-55378-5","volume":"16","author":"B Alsaed","year":"2025","unstructured":"Alsaed B, Lin L, Son J, Li J, Smolander J, Lopezet T, et al. Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment. Nat Commun. 2025;16(1):28. https:\/\/doi.org\/10.1038\/s41467-024-55378-5.","journal-title":"Nat Commun"},{"issue":"6","key":"4314_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17061027","volume":"17","author":"MS Oh","year":"2025","unstructured":"Oh MS, Abascal J, Rennels AK, Salehi-Rad R, Dubinett SM, Liu B. Tumor heterogeneity and the immune response in non-small cell lung cancer: emerging insights and implications for immunotherapy. Cancers. 2025;17(6):1027. https:\/\/doi.org\/10.3390\/cancers17061027.","journal-title":"Cancers"},{"issue":"15","key":"4314_CR41","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.3390\/cancers17152423","volume":"17","author":"H Khan","year":"2025","unstructured":"Khan H, Su Z, Zhang H, Wang Y, Ning B, Wei S, et al. Predicting neoadjuvant chemotherapy response in triple-negative breast cancer using pre-treatment histopathologic images. Cancers. 2025;17(15):2423. https:\/\/doi.org\/10.3390\/cancers17152423.","journal-title":"Cancers"},{"issue":"1","key":"4314_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03322-4","volume":"16","author":"N Sinai Borker","year":"2025","unstructured":"Sinai Borker N, Sajimon J, Subhadarshini S, Aara R, Jolly MK, Prabhu JS, et al. Role of intratumoral heterogeneity in metastatic progression and drug resistance. Discov Oncol. 2025;16(1):1689. https:\/\/doi.org\/10.1007\/s12672-025-03322-4.","journal-title":"Discov Oncol"},{"issue":"3","key":"4314_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2024.152805","volume":"229","author":"J Tang","year":"2024","unstructured":"Tang J, Ming L, Qin F, Qin Y, Wang D, Huang L, et al. The heterogeneity of tumour-associated macrophages contributes to the clinical outcomes and indications for immune checkpoint blockade in colorectal cancer patients. Immunobiology. 2024;229(3):152805. https:\/\/doi.org\/10.1016\/j.imbio.2024.152805.","journal-title":"Immunobiology"},{"issue":"12","key":"4314_CR44","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941\u20134. https:\/\/doi.org\/10.2967\/jnumed.116.178673.","journal-title":"J Nucl Med"},{"key":"4314_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1655693","volume":"12","author":"X Zhao","year":"2025","unstructured":"Zhao X, Xiong J, Li D, Zhang Y. Clinical trials of nanoparticle-enhanced CAR-T and NK cell therapies in oncology: overcoming translational and clinical challenges - a mini review. Front Med. 2025;12:1655693. https:\/\/doi.org\/10.3389\/fmed.2025.1655693.","journal-title":"Front Med"},{"issue":"1","key":"4314_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03734-w","volume":"25","author":"YC Fu","year":"2025","unstructured":"Fu YC, Liang SB, Luo M, Wang XP. Intratumoral heterogeneity and drug resistance in cancer. Cancer Cell Int. 2025;25(1):103. https:\/\/doi.org\/10.1186\/s12935-025-03734-w.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"4314_CR47","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1056\/NEJMoa2501796","volume":"393","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Im SA, Saura C, Loibl S, Kalinsky K, Schmid P, et al. Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2025;393(2):151\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2501796.","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"4314_CR48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.1003","volume":"43","author":"NC Turner","year":"2025","unstructured":"Turner NC. INAVO120: phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)\/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2\u2013), endocrine-resistant advanced breast cancer (aBC). J Clin Oncol. 2025;43(suppl 16):1003. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.1003.","journal-title":"J Clin Oncol"},{"key":"4314_CR49","unstructured":"Helwick C. Emerging success with novel targeted therapies in endocrine-resistant metastatic breast cancer. ASCO Post. 2025."},{"issue":"28","key":"4314_CR50","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1200\/JCO-25-00663","volume":"43","author":"S Wedam","year":"2025","unstructured":"Wedam S, Narayan P, Gittleman H, Cheng J, Bhatnagar V, Sabit H, et al. US Food and Drug Administration approval summary: inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer. J Clin Oncol. 2025;43(28):3123\u201331. https:\/\/doi.org\/10.1200\/JCO-25-00663.","journal-title":"J Clin Oncol"},{"issue":"19","key":"4314_CR51","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.23.01909","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, et al. Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. J Clin Oncol. 2024;42(19):2281\u201394. https:\/\/doi.org\/10.1200\/JCO.23.01909.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4314_CR52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia A, Jhaveri K, Kalinsky K, Pernas S, Tsurutani J, Xu B, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2025;43(3):285\u201396. https:\/\/doi.org\/10.1200\/JCO.24.00920.","journal-title":"J Clin Oncol"},{"issue":"35","key":"4314_CR53","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2217\/fon-2023-0228","volume":"19","author":"RA Dent","year":"2023","unstructured":"Dent RA, Cescon DW, Bachelot T, Jung KH, Shao ZM, Saji S, et al. TROPION-Breast02: datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol. 2023;19(35):2349\u201359. https:\/\/doi.org\/10.2217\/fon-2023-0228.","journal-title":"Future Oncol"},{"issue":"8","key":"4314_CR54","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1814213.","journal-title":"N Engl J Med"},{"issue":"8","key":"4314_CR55","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaoncol.2018.7147","volume":"5","author":"S Adams","year":"2019","unstructured":"Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, et al. Current landscape of immunotherapy in breast cancer: a review. JAMA Oncol. 2019;5(8):1205\u201314. https:\/\/doi.org\/10.1001\/jamaoncol.2018.7147.","journal-title":"JAMA Oncol"},{"key":"4314_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1602529","volume":"16","author":"N Vatsavai","year":"2025","unstructured":"Vatsavai N, Kaur Bhinder S, Shaik R, Mahira S, Kapoor S, Ali MS, et al. Advances and challenges in cancer immunotherapy: mechanisms, clinical applications, and future directions. Front Pharmacol. 2025;16:1602529. https:\/\/doi.org\/10.3389\/fphar.2025.1602529.","journal-title":"Front Pharmacol"},{"key":"4314_CR57","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/JEP.S267383","volume":"13","author":"PB Tchounwou","year":"2021","unstructured":"Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S. Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. J Exp Pharmacol. 2021;13:303\u201328. https:\/\/doi.org\/10.2147\/JEP.S267383.","journal-title":"J Exp Pharmacol"},{"issue":"1","key":"4314_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-025-01961-6","volume":"17","author":"X Yu","year":"2025","unstructured":"Yu X, Jia L, Tang Q, Zhou Q, Wang G, Wang S. Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms. Clin Epigenetics. 2025;17(1):145. https:\/\/doi.org\/10.1186\/s13148-025-01961-6.","journal-title":"Clin Epigenetics"},{"issue":"11","key":"4314_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115261","volume":"26","author":"AI Morgovan","year":"2025","unstructured":"Morgovan AI, Boia ER, Motofelea AC, Orasan A, Negru MC, Guran K, et al. Advances in nanotechnology-based cisplatin delivery for ORL cancers: a comprehensive review. Int J Mol Sci. 2025;26(11):5261. https:\/\/doi.org\/10.3390\/ijms26115261.","journal-title":"Int J Mol Sci"},{"key":"4314_CR60","unstructured":"Awosika AO, Farrar MC, Jacobs TF. Paclitaxel. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK536917\/"},{"issue":"5","key":"4314_CR61","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","volume":"31","author":"SS Jiang","year":"2023","unstructured":"Jiang SS, Xie YL, Xiao XY, Kang ZR, Lin XL, Zhang L, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe. 2023;31(5):781-97.e9. https:\/\/doi.org\/10.1016\/j.chom.2023.04.010.","journal-title":"Cell Host Microbe"},{"key":"4314_CR62","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12935-024-03415-0","volume":"24","author":"AI Alalawy","year":"2024","unstructured":"Alalawy AI. Key genes and molecular mechanisms related to paclitaxel resistance. Cancer Cell Int. 2024;24:244. https:\/\/doi.org\/10.1186\/s12935-024-03415-0.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"4314_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70098","volume":"13","author":"M Johnson","year":"2025","unstructured":"Johnson M, Lin YW, Schmidt H, Sunnaker M, Maanen EV, Huang X, et al. Population pharmacokinetics of osimertinib in patients with non-small cell lung cancer. Pharmacol Res Perspect. 2025;13(3):e70098. https:\/\/doi.org\/10.1002\/prp2.70098.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"4314_CR64","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/jcph.1035","volume":"58","author":"K Vishwanathan","year":"2018","unstructured":"Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, et al. The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small-cell lung cancer and in healthy volunteers. J Clin Pharmacol. 2018;58(4):474\u201384. https:\/\/doi.org\/10.1002\/jcph.1035.","journal-title":"J Clin Pharmacol"},{"key":"4314_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63743-z","volume":"14","author":"F Liang","year":"2024","unstructured":"Liang F, Zhang Y, Xue Q, Zhang X. Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases. Sci Rep. 2024;14:12736. https:\/\/doi.org\/10.1038\/s41598-024-63743-z.","journal-title":"Sci Rep"},{"issue":"24","key":"4314_CR66","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1809697.","journal-title":"N Engl J Med"},{"issue":"5","key":"4314_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050821","volume":"17","author":"S Bandara","year":"2025","unstructured":"Bandara S, Raveendran S. Current landscape and future directions in cancer immunotherapy: therapies, trials, and challenges. Cancers. 2025;17(5):821. https:\/\/doi.org\/10.3390\/cancers17050821.","journal-title":"Cancers"},{"issue":"1","key":"4314_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40. https:\/\/doi.org\/10.1186\/s12943-023-01740-y.","journal-title":"Mol Cancer"},{"issue":"2","key":"4314_CR69","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1903835.","journal-title":"N Engl J Med"},{"issue":"1","key":"4314_CR70","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307.","journal-title":"N Engl J Med"},{"issue":"15","key":"4314_CR71","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40(15):1616\u201322. https:\/\/doi.org\/10.1200\/JCO.22.00193.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4314_CR72","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1704174.","journal-title":"N Engl J Med"},{"issue":"9","key":"4314_CR73","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.acuroe.2024.05.008","volume":"48","author":"\u00c1 Borque-Fernando","year":"2024","unstructured":"Borque-Fernando \u00c1, Zapatero A, Manneh R, Alonso-Gordoa T, Cou\u00f1ago F, Dom\u00ednguez-Esteban M, et al. Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: patient selection. Actas Urol\u00f3gicas Espa\u00f1olas (English Edition). 2024;48(9):623\u201331. https:\/\/doi.org\/10.1016\/j.acuroe.2024.05.008.","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"},{"issue":"10336","key":"4314_CR74","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design. Lancet. 2022;399(10336):1695\u2013707. https:\/\/doi.org\/10.1016\/S0140-6736(22)00367-1.","journal-title":"Lancet"},{"issue":"12","key":"4314_CR75","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2119115.","journal-title":"N Engl J Med"},{"issue":"2","key":"4314_CR76","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86(2):148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"issue":"2","key":"4314_CR77","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3349\/ymj.2022.0244","volume":"64","author":"K Park","year":"2023","unstructured":"Park K, Kim JY, Park I, Shin SH, Lee HJ, Lee JL. Effectiveness of adding docetaxel to androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean real-world practice. Yonsei Med J. 2023;64(2):86\u201393. https:\/\/doi.org\/10.3349\/ymj.2022.0244.","journal-title":"Yonsei Med J"},{"issue":"10162","key":"4314_CR78","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clark NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(18)32486-3.","journal-title":"Lancet"},{"key":"4314_CR79","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/RRU.S303215","volume":"14","author":"E Choi","year":"2022","unstructured":"Choi E, Buie J, Camacho J, Sharma P, de Riese WTW. Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers. Res Rep Urol. 2022;14:87\u2013108. https:\/\/doi.org\/10.2147\/RRU.S303215.","journal-title":"Res Rep Urol"},{"issue":"1-2","key":"4314_CR80","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ddstr.2011.02.004","volume":"7","author":"JB Aragon-Ching","year":"2010","unstructured":"Aragon-Ching JB, Dahut WL. Novel androgen deprivation therapy (ADT) in the treatment of advanced prostate cancer. Drug Discov Today Ther Strateg. 2010;7(1\u20132):31\u20135. https:\/\/doi.org\/10.1016\/j.ddstr.2011.02.004.","journal-title":"Drug Discov Today Ther Strateg"},{"key":"4314_CR81","doi-asserted-by":"publisher","unstructured":"Huang F, Li K, Shevach JW, Wang Q. Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer. J Natl Cancer Cent. 2025;Advance online publication. https:\/\/doi.org\/10.1016\/j.jncc.2025.04.004","DOI":"10.1016\/j.jncc.2025.04.004"},{"issue":"8","key":"4314_CR82","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1503747.","journal-title":"N Engl J Med"},{"key":"4314_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1157306","volume":"14","author":"M Sousa-Pimenta","year":"2023","unstructured":"Sousa-Pimenta M, Estevinho LM, Szopa A, Basit M, Khan K, Armaghan M, et al. Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel. Front Pharmacol. 2023;14:1157306. https:\/\/doi.org\/10.3389\/fphar.2023.1157306.","journal-title":"Front Pharmacol"},{"issue":"3","key":"4314_CR84","first-page":"110","volume":"22","author":"ND Shore","year":"2020","unstructured":"Shore ND. Current and future management of locally advanced and metastatic prostate cancer. Rev Urol. 2020;22(3):110\u201323.","journal-title":"Rev Urol"},{"issue":"4","key":"4314_CR85","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1586\/14737175.4.4.691","volume":"4","author":"C Nieder","year":"2004","unstructured":"Nieder C, Grosu AL, Mehta MP, Andratschke N, Molls M. Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents. Expert Rev Neurother. 2004;4(4):691\u2013703. https:\/\/doi.org\/10.1586\/14737175.4.4.691.","journal-title":"Expert Rev Neurother"},{"key":"4314_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583363","volume":"16","author":"H Lu","year":"2025","unstructured":"Lu H, Teng Z, Wang J, Zhang W. Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors. Front Immunol. 2025;16:1583363. https:\/\/doi.org\/10.3389\/fimmu.2025.1583363.","journal-title":"Front Immunol"},{"issue":"9","key":"4314_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163366","volume":"11","author":"EA Sickmier","year":"2016","unstructured":"Sickmier EA, Kurzeja RJ, Michelsen K, Vazir M, Yang E, Tasker AS. The Panitumumab EGFR complex reveals a binding mechanism that overcomes Cetuximab induced resistance. PLoS ONE. 2016;11(9):e0163366. https:\/\/doi.org\/10.1371\/journal.pone.0163366.","journal-title":"PLoS ONE"},{"issue":"14","key":"4314_CR88","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408\u201317. https:\/\/doi.org\/10.1056\/NEJMoa0805019.","journal-title":"N Engl J Med"},{"issue":"23","key":"4314_CR89","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335\u201342. https:\/\/doi.org\/10.1056\/NEJMoa032691.","journal-title":"N Engl J Med"},{"issue":"9863","key":"4314_CR90","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(12)61900-X.","journal-title":"Lancet"},{"issue":"23","key":"4314_CR91","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2017699.","journal-title":"N Engl J Med"},{"issue":"2","key":"4314_CR92","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","volume":"40","author":"HJ Lenz","year":"2022","unstructured":"Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol. 2022;40(2):161\u201370. https:\/\/doi.org\/10.1200\/JCO.21.01015.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4314_CR93","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003.","journal-title":"Ann Oncol"},{"issue":"1","key":"4314_CR94","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcaa002","volume":"2","author":"C Bailly","year":"2020","unstructured":"Bailly C, Thuru X, Quesnel B. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer. 2020;2(1):zcaa002. https:\/\/doi.org\/10.1093\/narcan\/zcaa002.","journal-title":"NAR Cancer"},{"issue":"5","key":"4314_CR95","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330\u20138. https:\/\/doi.org\/10.1038\/nrc1074.","journal-title":"Nat Rev Cancer"},{"issue":"9209","key":"4314_CR96","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(00)02034-1.","journal-title":"Lancet"},{"issue":"11","key":"4314_CR97","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","volume":"22","author":"J Cassidy","year":"2004","unstructured":"Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22(11):2084\u201391. https:\/\/doi.org\/10.1200\/JCO.2004.11.069.","journal-title":"J Clin Oncol"},{"key":"4314_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101332","volume":"16","author":"S Su","year":"2022","unstructured":"Su S, Chhabra G, Singh CK, Ndiaye MA, Ahmad N. PLK1 inhibition-based combination therapies for cancer management. Transl Oncol. 2022;16:101332. https:\/\/doi.org\/10.1016\/j.tranon.2021.101332.","journal-title":"Transl Oncol"},{"issue":"9","key":"4314_CR99","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-08-2445","volume":"15","author":"D Rudolph","year":"2009","unstructured":"Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, et al. BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res. 2009;15(9):3094\u2013102. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2445.","journal-title":"Clin Cancer Res"},{"key":"4314_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433315","volume":"15","author":"B Yu","year":"2024","unstructured":"Yu B, Kang J, Lei H, Li Z, Yang H, Zhang M. Immunotherapy for colorectal cancer. Front Immunol. 2024;15:1433315. https:\/\/doi.org\/10.3389\/fimmu.2024.1433315.","journal-title":"Front Immunol"},{"issue":"4","key":"4314_CR101","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/mco2.103","volume":"2","author":"M Wang","year":"2021","unstructured":"Wang M, Chen S, Ao D. Targeting DNA repair pathway in cancer: Mechanisms and clinical application. MedComm. 2021;2(4):654\u201391. https:\/\/doi.org\/10.1002\/mco2.103.","journal-title":"MedComm"},{"issue":"9","key":"4314_CR102","doi-asserted-by":"publisher","first-page":"12513","DOI":"10.1007\/s13277-016-5111-1","volume":"37","author":"P Wang","year":"2016","unstructured":"Wang P, Ma D, Wang J, Fang Q, Gao R, Wu W, et al. INPP4B-mediated DNA repair pathway confers resistance to chemotherapy in acute myeloid leukemia. Tumour Biol. 2016;37(9):12513\u201323. https:\/\/doi.org\/10.1007\/s13277-016-5111-1.","journal-title":"Tumour Biol"},{"issue":"4","key":"4314_CR103","doi-asserted-by":"publisher","first-page":"965","DOI":"10.20517\/cdr.2021.66","volume":"4","author":"S Kambhampati","year":"2021","unstructured":"Kambhampati S, Song JY, Herrera AF, Chan WC. Barriers to achieving a cure in lymphoma. Cancer Drug Resist. 2021;4(4):965\u201383. https:\/\/doi.org\/10.20517\/cdr.2021.66.","journal-title":"Cancer Drug Resist"},{"key":"4314_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100992","volume":"57","author":"MJ Gordon","year":"2023","unstructured":"Gordon MJ, Smith MR, Nastoupil LJ. Follicular lymphoma: The long and winding road leading to your cure? Blood Rev. 2023;57:100992. https:\/\/doi.org\/10.1016\/j.blre.2022.100992.","journal-title":"Blood Rev"},{"issue":"5","key":"4314_CR105","doi-asserted-by":"publisher","first-page":"966","DOI":"10.3390\/cancers13050966","volume":"13","author":"R Di Francia","year":"2021","unstructured":"Di Francia R, Crisci S, De Monaco A, Cafiero C, Re A, Iaccarino G, et al. Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers. Cancers (Basel). 2021;13(5):966. https:\/\/doi.org\/10.3390\/cancers13050966.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4314_CR106","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253\u201365. https:\/\/doi.org\/10.1038\/nrc1317.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"4314_CR107","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","volume":"28","author":"S Goel","year":"2018","unstructured":"Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4\/6 inhibition in cancer: Beyond cell cycle arrest. Trends Cell Biol. 2018;28(11):911\u201325. https:\/\/doi.org\/10.1016\/j.tcb.2018.07.002.","journal-title":"Trends Cell Biol"},{"issue":"8","key":"4314_CR108","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3390\/cancers16081599","volume":"16","author":"P Bl\u00fcm","year":"2024","unstructured":"Bl\u00fcm P, Kayser S. Chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies: clinical implications and limitations. Cancers (Basel). 2024;16(8):1599. https:\/\/doi.org\/10.3390\/cancers16081599.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4314_CR109","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/2399369319837212","volume":"3","author":"K Sury","year":"2019","unstructured":"Sury K. Update on the prevention and treatment of tumor lysis syndrome. J Onco-Nephrol. 2019;3(1):19\u201330. https:\/\/doi.org\/10.1177\/2399369319837212.","journal-title":"J Onco-Nephrol"},{"key":"4314_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153. https:\/\/doi.org\/10.3389\/fimmu.2022.927153.","journal-title":"Front Immunol"},{"key":"4314_CR111","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W, Liu Y, He Z, Li L, Liu S, Jiang M, et al. Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discov. 2024;10:40. https:\/\/doi.org\/10.1038\/s41420-024-01815-9.","journal-title":"Cell Death Discov"},{"key":"4314_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155600","volume":"129","author":"J Zhang","year":"2024","unstructured":"Zhang J, Wu Y, Li Y, Li S, Liu J, Yang X, et al. Natural products and derivatives for breast cancer treatment: from drug discovery to molecular mechanism. Phytomedicine. 2024;129:155600. https:\/\/doi.org\/10.1016\/j.phymed.2024.155600.","journal-title":"Phytomedicine"},{"key":"4314_CR113","doi-asserted-by":"publisher","unstructured":"Alam M, Gulzar M, Akhtar MS,Rashid S, Zulfareen, Tanuja,\u00a0et al. Epigallocatechin-3-gallate therapeutic potential in human diseases: molecular mechanisms and clinical studies. Mol Biomed. 2024;5:73. https:\/\/doi.org\/10.1186\/s43556-024-00240-9","DOI":"10.1186\/s43556-024-00240-9"},{"issue":"12","key":"4314_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18122589","volume":"18","author":"JH Ko","year":"2017","unstructured":"Ko JH, Sethi G, Um JY, Shanmugam MK, Arfuso F, Kumar AP, et al. The role of resveratrol in cancer therapy. Int J Mol Sci. 2017;18(12):2589. https:\/\/doi.org\/10.3390\/ijms18122589.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4314_CR115","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4155\/ppa-2017-0030","volume":"7","author":"A Sharma","year":"2018","unstructured":"Sharma A, Kashyap D, Sak K, Tuli HS, Sharma AK. Therapeutic charm of quercetin and its derivatives: a review of research and patents. Pharm Pat Anal. 2018;7(1):15\u201332. https:\/\/doi.org\/10.4155\/ppa-2017-0030.","journal-title":"Pharm Pat Anal"},{"issue":"7","key":"4314_CR116","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/jamadermatol.2022.1736","volume":"158","author":"H Zhao","year":"2022","unstructured":"Zhao H, Zhu W, Zhao X, Li X, Zhou Z, Zheng M, et al. Efficacy of epigallocatechin-3-gallate in preventing dermatitis in patients with breast cancer receiving postoperative radiotherapy: a double-blind, placebo-controlled, phase 2 randomized clinical trial. JAMA Dermatol. 2022;158(7):779\u201386. https:\/\/doi.org\/10.1001\/jamadermatol.2022.1736.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"4314_CR117","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1667\/RR3255.1","volume":"180","author":"JL Ryan","year":"2013","unstructured":"Ryan JL, Heckler CE, Ling M, Katz A, Williams JP, Pentland AP, et al. Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients. Radiat Res. 2013;180(1):34\u201343. https:\/\/doi.org\/10.1667\/RR3255.1.","journal-title":"Radiat Res"},{"issue":"1","key":"4314_CR118","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10549-023-07223-4","volume":"205","author":"M Lustberg","year":"2024","unstructured":"Lustberg M, Fan-Havard P, Wong FL, Hill K, Phelps MA, Herrera KW, et al. Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance\/NCORP pilot trial. Breast Cancer Res Treat. 2024;205(1):61\u201373. https:\/\/doi.org\/10.1007\/s10549-023-07223-4.","journal-title":"Breast Cancer Res Treat"},{"key":"4314_CR119","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0223-0","volume":"12","author":"HH Chow","year":"2014","unstructured":"Chow HH, Garland LL, Heckman-Stoddard BM, Hsu CH, Butler VD, Cordova CA, et al. A pilot clinical study of resveratrol in postmenopausal women with high body mass index: effects on systemic sex steroid hormones. J Transl Med. 2014;12:223. https:\/\/doi.org\/10.1186\/s12967-014-0223-0.","journal-title":"J Transl Med"},{"key":"4314_CR120","doi-asserted-by":"publisher","first-page":"9155","DOI":"10.2147\/IJN.S518174","volume":"20","author":"ZY Wu","year":"2025","unstructured":"Wu ZY, Qiu KY, Gai YJ, Wu JH, Zhou BX, Shi QF. Quercetin: a natural ally in combating breast cancer. Int J Nanomedicine. 2025;20:9155\u201377. https:\/\/doi.org\/10.2147\/IJN.S518174.","journal-title":"Int J Nanomedicine"},{"issue":"10","key":"4314_CR121","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/pros.21147","volume":"70","author":"H Ide","year":"2010","unstructured":"Ide H, Tokiwa S, Sakamaki K, Nishio K, Isotani S, Muto S, et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate. 2010;70(10):1127\u201333. https:\/\/doi.org\/10.1002\/pros.21147.","journal-title":"Prostate"},{"key":"4314_CR122","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3892\/ijmm.2012.966","volume":"30","author":"Y Lee","year":"2012","unstructured":"Lee Y, Kwak J, Choi H, Choi KC, Kim S, Lee J, et al. EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity. Int J Mol Med. 2012;30:69\u201374. https:\/\/doi.org\/10.3892\/ijmm.2012.966.","journal-title":"Int J Mol Med"},{"key":"4314_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-018-1400-z","volume":"16","author":"AB Ward","year":"2018","unstructured":"Ward AB, Mir H, Kapur N, Gales DN, Carriere PP, Singh S. Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways. World J Surg Oncol. 2018;16:108. https:\/\/doi.org\/10.1186\/s12957-018-1400-z.","journal-title":"World J Surg Oncol"},{"key":"4314_CR124","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jsbmb.2013.12.010","volume":"140","author":"AM Mahmoud","year":"2014","unstructured":"Mahmoud AM, Yang W, Bosland MC. Soy isoflavones and prostate cancer: a review of molecular mechanisms. J Steroid Biochem Mol Biol. 2014;140:116\u201332. https:\/\/doi.org\/10.1016\/j.jsbmb.2013.12.010.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"11","key":"4314_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113203","volume":"12","author":"ES Seltzer","year":"2020","unstructured":"Seltzer ES, Watters AK, MacKenzie D Jr, Granat LM, Zhang D. Cannabidiol (CBD) as a promising anti-cancer drug. Cancers (Basel). 2020;12(11):3203. https:\/\/doi.org\/10.3390\/cancers12113203.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"4314_CR126","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1158\/1940-6207.CAPR-15-0098","volume":"8","author":"J Cho","year":"2015","unstructured":"Cho J, Rho O, Junco J, Carbajal S, Siegel D, Slaga TJ, et al. Effect of combined treatment with ursolic acid and resveratrol on skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Prev Res (Phila). 2015;8(9):817\u201325. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-15-0098.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"4314_CR127","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/03915603231202304","volume":"91","author":"BD Besasie","year":"2024","unstructured":"Besasie BD, Saha A, DiGiovanni J, Liss MA. Effects of curcumin and ursolic acid in prostate cancer: a systematic review. Urologia. 2024;91(1):90\u2013106. https:\/\/doi.org\/10.1177\/03915603231202304.","journal-title":"Urologia"},{"issue":"16","key":"4314_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163988","volume":"14","author":"NB Kumar","year":"2022","unstructured":"Kumar NB, Hogue S, Pow-Sang J, Poch M, Manley BJ, Li R, et al. Effects of green tea catechins on prostate cancer chemoprevention: the role of the gut microbiome. Cancers. 2022;14(16):3988. https:\/\/doi.org\/10.3390\/cancers14163988.","journal-title":"Cancers"},{"issue":"20","key":"4314_CR129","doi-asserted-by":"publisher","first-page":"11849","DOI":"10.1021\/acsomega.0c01818","volume":"5","author":"B Salehi","year":"2020","unstructured":"Salehi B, Machin L, Monzote L, Sharifi-Rad J, Ezzat SM, Salem MA, et al. Therapeutic potential of quercetin: new insights and perspectives for human health. ACS Omega. 2020;5(20):11849\u201372. https:\/\/doi.org\/10.1021\/acsomega.0c01818.","journal-title":"ACS Omega"},{"issue":"3","key":"4314_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031114","volume":"26","author":"V Naponelli","year":"2025","unstructured":"Naponelli V, Piscazzi A, Mangieri D. Cellular and molecular mechanisms modulated by genistein in cancer. Int J Mol Sci. 2025;26(3):1114. https:\/\/doi.org\/10.3390\/ijms26031114.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4314_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092505","volume":"15","author":"ZW Myint","year":"2023","unstructured":"Myint ZW, St Clair WH, Strup SE, Yan D, Li N, Allison DB, et al. A phase I dose escalation and expansion study of Epidiolex (cannabidiol) in patients with biochemically recurrent prostate cancer. Cancers. 2023;15(9):2505. https:\/\/doi.org\/10.3390\/cancers15092505.","journal-title":"Cancers"},{"key":"4314_CR132","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.semcancer.2016.06.003","volume":"40","author":"G Kallifatidis","year":"2016","unstructured":"Kallifatidis G, Hoy JJ, Lokeshwar BL. Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer. Semin Cancer Biol. 2016;40:160\u20139. https:\/\/doi.org\/10.1016\/j.semcancer.2016.06.003.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"4314_CR133","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.3892\/mmr.2019.9862","volume":"19","author":"L Li","year":"2019","unstructured":"Li L, Xu X, Wu L, Zhu H, He Z, Zhang B, et al. Scutellaria barbata polysaccharides inhibit tumor growth and affect the serum proteomic profiling of hepatoma H22-bearing mice. Mol Med Rep. 2019;19(3):2254\u201362. https:\/\/doi.org\/10.3892\/mmr.2019.9862.","journal-title":"Mol Med Rep"},{"issue":"5","key":"4314_CR134","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3892\/ol.2021.13011","volume":"22","author":"X Yang","year":"2021","unstructured":"Yang X, Zheng Y, Liu L, Huang J, Wang F, Zhang J. Progress on the study of the anticancer effects of artesunate. Oncol Lett. 2021;22(5):750. https:\/\/doi.org\/10.3892\/ol.2021.13011.","journal-title":"Oncol Lett"},{"key":"4314_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106487","volume":"185","author":"G Chen","year":"2022","unstructured":"Chen G, Zhu X, Li J, Zhang Y, Wang X, Zhang R, et al. Celastrol inhibits lung cancer growth by triggering histone acetylation and acting synergically with HDAC inhibitors. Pharmacol Res. 2022;185:106487. https:\/\/doi.org\/10.1016\/j.phrs.2022.106487.","journal-title":"Pharmacol Res"},{"issue":"Pt 2","key":"4314_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118999","volume":"337","author":"D Zhang","year":"2025","unstructured":"Zhang D, Wang Y, Yu P, Sun J, Li J, Hu Y, et al. Scutellarein inhibits lung cancer growth by inducing cell apoptosis and inhibiting glutamine metabolic pathway. J Ethnopharmacol. 2025;337(Pt 2):118999. https:\/\/doi.org\/10.1016\/j.jep.2024.118999.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"4314_CR137","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1142\/S0192415X12500152","volume":"40","author":"JW Hwang","year":"2012","unstructured":"Hwang JW, Oh JH, Yoo HS, Lee YW, Cho CK, Kwon KR, et al. Mountain ginseng extract exhibits anti-lung cancer activity by inhibiting the nuclear translocation of NF-\u03baB. Am J Chin Med. 2012;40(1):187\u2013202. https:\/\/doi.org\/10.1142\/S0192415X12500152.","journal-title":"Am J Chin Med"},{"issue":"65","key":"4314_CR138","doi-asserted-by":"publisher","first-page":"109340","DOI":"10.18632\/oncotarget.22677","volume":"8","author":"CC Chen","year":"2017","unstructured":"Chen CC, Kao CP, Chiu MM, Wang SH. The anti-cancer effects and mechanisms of Scutellaria barbata D. Don on CL1-5 lung cancer cells. Oncotarget. 2017;8(65):109340\u201357. https:\/\/doi.org\/10.18632\/oncotarget.22677.","journal-title":"Oncotarget"},{"issue":"3","key":"4314_CR139","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/jpp\/rgae039","volume":"77","author":"NT Thoa","year":"2025","unstructured":"Thoa NT, Son NT. Scutellarein: a review of chemistry and pharmacology. J Pharm Pharmacol. 2025;77(3):352\u201370. https:\/\/doi.org\/10.1093\/jpp\/rgae039.","journal-title":"J Pharm Pharmacol"},{"issue":"17","key":"4314_CR140","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29174134","volume":"29","author":"J Sun","year":"2024","unstructured":"Sun J, Cao Y, Liu Q, Zhou Z, Xu Y, Liu C. Chemical constituents, anti-tumor mechanisms, and clinical application: a comprehensive review on *Scutellaria barbata*. Molecules. 2024;29(17):4134. https:\/\/doi.org\/10.3390\/molecules29174134.","journal-title":"Molecules"},{"key":"4314_CR141","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jep.2016.02.012","volume":"182","author":"G Tao","year":"2016","unstructured":"Tao G, Balunas MJ. Current therapeutic role and medicinal potential of *Scutellaria barbata* in traditional Chinese medicine and Western research. J Ethnopharmacol. 2016;182:170\u201380. https:\/\/doi.org\/10.1016\/j.jep.2016.02.012.","journal-title":"J Ethnopharmacol"},{"key":"4314_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113705","volume":"155","author":"D Cao","year":"2022","unstructured":"Cao D, Chen D, Xia JN, Wang WY, Zhu GY, Chen LW, et al. Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation. Biomed Pharmacother. 2022;155:113705. https:\/\/doi.org\/10.1016\/j.biopha.2022.113705.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"4314_CR143","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.3892\/mmr.2020.11341","volume":"22","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Liu J, Liu L. Artesunate inhibits lung cancer cells via regulation of mitochondrial membrane potential and induction of apoptosis. Mol Med Rep. 2020;22(4):3017\u201322. https:\/\/doi.org\/10.3892\/mmr.2020.11341.","journal-title":"Mol Med Rep"},{"key":"4314_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1483049","volume":"15","author":"X Fan","year":"2024","unstructured":"Fan X, Yan Y, Li Y, Song Y, Li B. Anti-tumor mechanism of artesunate. Front Pharmacol. 2024;15:1483049. https:\/\/doi.org\/10.3389\/fphar.2024.1483049.","journal-title":"Front Pharmacol"},{"key":"4314_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114882","volume":"163","author":"C Wang","year":"2023","unstructured":"Wang C, Dai S, Zhao X, Zhang Y, Gong L, Fu K, et al. Celastrol as an emerging anticancer agent: current status, challenges and therapeutic strategies. Biomed Pharmacother. 2023;163:114882. https:\/\/doi.org\/10.1016\/j.biopha.2023.114882.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"4314_CR146","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.3892\/ol.2017.7593","volume":"15","author":"YF Yan","year":"2018","unstructured":"Yan YF, Zhang HH, Lv Q, Liu YM, Li YJ, Li BS, et al. Celastrol suppresses the proliferation of lung adenocarcinoma cells by regulating microRNA-24 and microRNA-181b. Oncol Lett. 2018;15(2):2515\u201321. https:\/\/doi.org\/10.3892\/ol.2017.7593.","journal-title":"Oncol Lett"},{"issue":"1","key":"4314_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01589-z","volume":"8","author":"X Xie","year":"2023","unstructured":"Xie X, Yu T, Li X, Zhang N, Foster LJ, Peng C, et al. Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials. Signal Transduct Target Ther. 2023;8(1):335. https:\/\/doi.org\/10.1038\/s41392-023-01589-z.","journal-title":"Signal Transduct Target Ther"},{"key":"4314_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116294","volume":"173","author":"P Chaudhary","year":"2024","unstructured":"Chaudhary P, Janmeda P, Pareek A, Chuturgoon AA, Sharma R, Pareek A. Etiology of lung carcinoma and treatment through medicinal plants, marine plants and green synthesized nanoparticles: a comprehensive review. Biomed Pharmacother. 2024;173:116294. https:\/\/doi.org\/10.1016\/j.biopha.2024.116294.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"4314_CR149","doi-asserted-by":"publisher","DOI":"10.3390\/nu14122413","volume":"14","author":"J Li","year":"2022","unstructured":"Li J, Fan Y, Zhang Y, Liu Y, Yu Y, Ma M. Resveratrol induces autophagy and apoptosis in non-small-cell lung cancer cells by activating the NGFR-AMPK-mTOR pathway. Nutrients. 2022;14(12):2413. https:\/\/doi.org\/10.3390\/nu14122413.","journal-title":"Nutrients"},{"issue":"2","key":"4314_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020506","volume":"19","author":"LQ Liu","year":"2018","unstructured":"Liu LQ, Li HS, Nie SP, Shen MY, Hu JL, Xie MY. Tea polysaccharide prevents colitis-associated carcinogenesis in mice by inhibiting the proliferation and invasion of tumor cells. Int J Mol Sci. 2018;19(2):506. https:\/\/doi.org\/10.3390\/ijms19020506.","journal-title":"Int J Mol Sci"},{"key":"4314_CR151","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.lfs.2019.02.049","volume":"221","author":"H Liu","year":"2019","unstructured":"Liu H, Wang J, Tao Y, Li X, Qin J, Bai Z, et al. Curcumol inhibits colorectal cancer proliferation by targeting miR-21 and modulated PTEN\/PI3K\/Akt pathways. Life Sci. 2019;221:354\u201361. https:\/\/doi.org\/10.1016\/j.lfs.2019.02.049.","journal-title":"Life Sci"},{"key":"4314_CR152","doi-asserted-by":"publisher","unstructured":"Song D, Fang X, Sun Z, Qiu Z, Liu D, Luo H, et al. Cryptotanshinone, a potential SIRT3 inhibitor, suppresses colorectal cancer proliferation in vitro and in vivo. Nat Prod Commun. 2023;18(8). https:\/\/doi.org\/10.1177\/1934578X231194808","DOI":"10.1177\/1934578X231194808"},{"key":"4314_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112610","volume":"138","author":"Y Chang","year":"2024","unstructured":"Chang Y, Ou Q, Zhou X, Nie K, Zheng P, Liu J, et al. Jianpi Jiedu decoction suppresses colorectal cancer growth by inhibiting M2 polarization of TAMs through the tryptophan metabolism-AhR pathway. Int Immunopharmacol. 2024;138:112610. https:\/\/doi.org\/10.1016\/j.intimp.2024.112610.","journal-title":"Int Immunopharmacol"},{"issue":"19","key":"4314_CR154","doi-asserted-by":"publisher","first-page":"7392","DOI":"10.1158\/0008-5472.CAN-10-2027","volume":"70","author":"KR Patel","year":"2010","unstructured":"Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010;70(19):7392\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2027.","journal-title":"Cancer Res"},{"issue":"Pt 2","key":"4314_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.147540","volume":"328","author":"AK Rashwan","year":"2025","unstructured":"Rashwan AK, El-Shiekh RA, Bassiony A, Abdelshafy AM, Osman AI, Younis HA, et al. Recent advances in chemical characterization, emerging applications, and biological activities of tea polysaccharides and their conjugates from leaves and flowers: A review. Int J Biol Macromol. 2025;328(Pt 2):147540-. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.147540.","journal-title":"Int J Biol Macromol"},{"key":"4314_CR156","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.961507","volume":"9","author":"Y Chen","year":"2022","unstructured":"Chen Y, Pan X, Tian B, Hu Y. Polysaccharide immunization and colorectal cancer: a systematic review and network meta-analysis. Front Nutr. 2022;9:961507. https:\/\/doi.org\/10.3389\/fnut.2022.961507.","journal-title":"Front Nutr"},{"issue":"7","key":"4314_CR157","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/jn\/nxz029","volume":"149","author":"LM Howells","year":"2019","unstructured":"Howells LM, Iwuji COO, Irving GRB, Barber S, Walter H, Sidat Z, et al. Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial. J Nutr. 2019;149(7):1133\u20139. https:\/\/doi.org\/10.1093\/jn\/nxz029.","journal-title":"J Nutr"},{"key":"4314_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-73234-9_1","volume":"1328","author":"Y Panahi","year":"2021","unstructured":"Panahi Y, Saberi-Karimian M, Valizadeh O, Behnam B, Saadat A, Jamialahmadi T, et al. Effects of curcuminoids on systemic inflammation and quality of life in patients with colorectal cancer undergoing chemotherapy: a randomized controlled trial. Adv Exp Med Biol. 2021;1328:1\u20139. https:\/\/doi.org\/10.1007\/978-3-030-73234-9_1.","journal-title":"Adv Exp Med Biol"},{"issue":"20","key":"4314_CR159","doi-asserted-by":"publisher","first-page":"11024","DOI":"10.3390\/ijms222011024","volume":"22","author":"IM Briata","year":"2021","unstructured":"Briata IM, Paleari L, Rutigliani M, Petrera M, Caviglia S, Romagnoli P, et al. A presurgical study of curcumin combined with anthocyanin supplements in patients with colorectal adenomatous polyps. Int J Mol Sci. 2021;22(20):11024. https:\/\/doi.org\/10.3390\/ijms222011024.","journal-title":"Int J Mol Sci"},{"key":"4314_CR160","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.653232","volume":"12","author":"X Fu","year":"2021","unstructured":"Fu X, Zhao W, Li K, Zhou J, Chen X. Cryptotanshinone inhibits the growth of HCT116 colorectal cancer cells through endoplasmic reticulum stress-mediated autophagy. Front Pharmacol. 2021;12:653232. https:\/\/doi.org\/10.3389\/fphar.2021.653232.","journal-title":"Front Pharmacol"},{"key":"4314_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116811","volume":"317","author":"L Zhang","year":"2023","unstructured":"Zhang L, Chen N, Zhan L, Bi T, Zhou W, Zhang L, et al. Erchen decoction alleviates obesity-related hepatic steatosis via modulating gut microbiota-drived butyric acid contents and promoting fatty acid \u03b2-oxidation. J Ethnopharmacol. 2023;317:116811. https:\/\/doi.org\/10.1016\/j.jep.2023.116811.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"4314_CR162","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bcp.2011.08.010","volume":"83","author":"M Russo","year":"2012","unstructured":"Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol. 2012;83(1):6\u201315. https:\/\/doi.org\/10.1016\/j.bcp.2011.08.010.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"4314_CR163","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31584","volume":"72","author":"NN Shah","year":"2025","unstructured":"Shah NN, Schafer ES, Chi YY, Malvar J, Heym KM, et al. Vincristine sulfate liposome injection with combination chemotherapy for children, adolescents, and young adults with relapsed acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium trial. Pediatr Blood Cancer. 2025;72(5):e31584. https:\/\/doi.org\/10.1002\/pbc.31584.","journal-title":"Pediatr Blood Cancer"},{"key":"4314_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2022.105472","volume":"85","author":"EC Filippi-Chiela","year":"2022","unstructured":"Filippi-Chiela EC, Vargas JE, Bueno E Silva MM, Thom\u00e9 MP, Lenz G. Vincristine promotes differential levels of apoptosis, mitotic catastrophe, and senescence depending on the genetic background of glioblastoma cells. Toxicol In Vitro. 2022;85:105472. https:\/\/doi.org\/10.1016\/j.tiv.2022.105472.","journal-title":"Toxicol In Vitro"},{"key":"4314_CR165","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12951-022-01554-y","volume":"20","author":"Y Zheng","year":"2022","unstructured":"Zheng Y, Jia R, Li J, Tian X, Qian Y. Curcumin- and resveratrol-co-loaded nanoparticles in synergistic treatment of hepatocellular carcinoma. J Nanobiotechnology. 2022;20:339. https:\/\/doi.org\/10.1186\/s12951-022-01554-y.","journal-title":"J Nanobiotechnology"},{"key":"4314_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108990","volume":"117","author":"D Liu","year":"2019","unstructured":"Liu D, Chen L, Zhao H, Vaziri ND, Ma SC, Zhao YY. Small molecules from natural products targeting the Wnt\/\u03b2-catenin pathway as a therapeutic strategy. Biomed Pharmacother. 2019;117:108990. https:\/\/doi.org\/10.1016\/j.biopha.2019.108990.","journal-title":"Biomed Pharmacother"},{"issue":"suppl 1","key":"4314_CR167","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112295","volume":"132","author":"BM William","year":"2018","unstructured":"William BM, Brillhart K, Afable M, Bakalarz K, Cooper B, Lazarus HM, et al. A phase II study of curcumin and vitamin D in previously untreated patients with early stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Blood. 2018;132(suppl 1):112295. https:\/\/doi.org\/10.1182\/blood-2018-99-112295.","journal-title":"Blood"},{"issue":"1","key":"4314_CR168","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12885-025-13751-7","volume":"25","author":"A Eghbali","year":"2025","unstructured":"Eghbali A, Adibifar M, Ghasemi A, Afzal RR, Moradi K, Eghbali A, et al. The effect of oral curcumin on vincristine-induced neuropathy in pediatric acute lymphoblastic leukemia: a double-blind randomized controlled clinical trial. BMC Cancer. 2025;25(1):344. https:\/\/doi.org\/10.1186\/s12885-025-13751-7.","journal-title":"BMC Cancer"},{"key":"4314_CR169","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3157867","volume":"2021","author":"SR Soofiyani","year":"2021","unstructured":"Soofiyani SR, Hosseini K, Forouhandeh H, Ghasemnejad T, Tarhriz V, Asgharian P, et al. Quercetin as a novel therapeutic approach for lymphoma. Oxid Med Cell Longev. 2021;2021:3157867. https:\/\/doi.org\/10.1155\/2021\/3157867.","journal-title":"Oxid Med Cell Longev"},{"key":"4314_CR170","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.biopha.2017.02.112","volume":"91","author":"B Zhu","year":"2017","unstructured":"Zhu B, Yu L, Yue Q. Co-delivery of vincristine and quercetin by nanocarriers for lymphoma combination chemotherapy. Biomed Pharmacother. 2017;91:287\u201394. https:\/\/doi.org\/10.1016\/j.biopha.2017.02.112.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"4314_CR171","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.18632\/aging.101250","volume":"9","author":"JA McCubrey","year":"2017","unstructured":"McCubrey JA, Lertpiriyapong K, Steelman LS, Abrams SL, Yang LV, Murata RM, et al. Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and micrornas. Aging. 2017;9(6):1477\u2013536. https:\/\/doi.org\/10.18632\/aging.101250.","journal-title":"Aging"},{"key":"4314_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-017-0038-6","volume":"1","author":"AY Berman","year":"2017","unstructured":"Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. npj Precis Oncol. 2017;1:35. https:\/\/doi.org\/10.1038\/s41698-017-0038-6.","journal-title":"npj Precis Oncol"},{"issue":"2","key":"4314_CR173","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","volume":"33","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379\u201389. https:\/\/doi.org\/10.1038\/s41375-018-0312-9.","journal-title":"Leukemia"},{"key":"4314_CR174","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10637-025-01528-5","volume":"43","author":"AA Awad","year":"2025","unstructured":"Awad AA, Shaban AY, Mohammed F, Marey MM, Aldemerdash MA, et al. Glasdegib combined with chemotherapy in the treatment of patients with acute myeloid leukemia: a comprehensive meta-analysis. Invest New Drugs. 2025;43:405\u201324. https:\/\/doi.org\/10.1007\/s10637-025-01528-5.","journal-title":"Invest New Drugs"},{"issue":"17","key":"4314_CR175","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27175452","volume":"27","author":"WH Talib","year":"2022","unstructured":"Talib WH, Awajan D, Hamed RA, Azzam AO, Mahmod AI, Al-Yasari IH. Combination anticancer therapies using selected phytochemicals. Molecules. 2022;27(17):5452. https:\/\/doi.org\/10.3390\/molecules27175452.","journal-title":"Molecules"},{"issue":"21","key":"4314_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111492","volume":"25","author":"B Mayo","year":"2024","unstructured":"Mayo B, Penroz S, Torres K, Sim\u00f3n L. Curcumin administration routes in breast cancer treatment. Int J Mol Sci. 2024;25(21):11492. https:\/\/doi.org\/10.3390\/ijms252111492.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4314_CR177","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","volume":"20","author":"AG Atanasov","year":"2021","unstructured":"Atanasov AG, Zotchev SB, Dirsch VM. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200\u201316. https:\/\/doi.org\/10.1038\/s41573-020-00114-z.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"4314_CR178","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.3390\/molecules20022728","volume":"20","author":"MK Shanmugam","year":"2015","unstructured":"Shanmugam MK, Rane G, Kanchi MM, Arfuso F, Chinnathambi A, Zayed ME, et al. The multifaceted role of curcumin in cancer prevention and treatment. Molecules. 2015;20(2):2728\u201369. https:\/\/doi.org\/10.3390\/molecules20022728.","journal-title":"Molecules"},{"issue":"6","key":"4314_CR179","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.biotechadv.2014.04.004","volume":"32","author":"S Prasad","year":"2014","unstructured":"Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: From bedside to bench and back. Biotechnol Adv. 2014;32(6):1053\u201364. https:\/\/doi.org\/10.1016\/j.biotechadv.2014.04.004.","journal-title":"Biotechnol Adv"},{"issue":"14","key":"4314_CR180","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25143146","volume":"25","author":"SA Almatroodi","year":"2020","unstructured":"Almatroodi SA, Almatroudi A, Khan AA, Alhumaydhi FA, Alsahli MA, Rahmani AH. Potential therapeutic targets of epigallocatechin gallate (EGCG), the most abundant catechin in green tea, and its role in the therapy of various types of cancer. Molecules. 2020;25(14):3146. https:\/\/doi.org\/10.3390\/molecules25143146.","journal-title":"Molecules"},{"issue":"7","key":"4314_CR181","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/jamadermatol.2022.1736","volume":"158","author":"H Zhao","year":"2022","unstructured":"Zhao H, Zhu W, Zhao X, Li X, Zheng M, Meng X, et al. Efficacy of epigallocatechin-3-gallate in preventing dermatitis in patients with breast cancer receiving postoperative radiotherapy: A double-blind, placebo-controlled, phase 2 randomized clinical trial. JAMA Dermatol. 2022;158(7):779\u201386. https:\/\/doi.org\/10.1001\/jamadermatol.2022.1736.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"4314_CR182","doi-asserted-by":"publisher","DOI":"10.1080\/09540105.2023.2280524","volume":"34","author":"M Shahbaz","year":"2023","unstructured":"Shahbaz M, Imran M, Hussain M, Alsagaby SA, Momal U, Naeem H, et al. Curcumin: A bioactive compound with molecular targets for human malignancies. Food Agric Immunol. 2023;34(1):2280524. https:\/\/doi.org\/10.1080\/09540105.2023.2280524.","journal-title":"Food Agric Immunol"},{"issue":"70","key":"4314_CR183","doi-asserted-by":"publisher","first-page":"40873","DOI":"10.1039\/c9ra08202f","volume":"9","author":"L Diao","year":"2019","unstructured":"Diao L, Shen A, Yang Y, Tao J, Hu Y. CD44-targeted hyaluronic acid\u2013curcumin reverses chemotherapeutics resistance by inhibiting P-gp and anti-apoptotic pathways. RSC Adv. 2019;9(70):40873\u201382. https:\/\/doi.org\/10.1039\/c9ra08202f.","journal-title":"RSC Adv"},{"key":"4314_CR184","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.neuro.2020.10.004","volume":"81","author":"GZ Li","year":"2020","unstructured":"Li GZ, Hu YH, Li DY, Zhang Y, Guo HL, Li YM, et al. Vincristine-induced peripheral neuropathy: A mini-review. Neurotoxicology. 2020;81:161\u201371. https:\/\/doi.org\/10.1016\/j.neuro.2020.10.004.","journal-title":"Neurotoxicology"},{"key":"4314_CR185","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s40843-020-1627-4","volume":"64","author":"Y Sun","year":"2021","unstructured":"Sun Y, Hu H, Jing X, Meng Q, Yu B, Cong H, et al. Co-delivery of chemotherapeutic drugs and cell cycle regulatory agents using nanocarriers for cancer therapy. Sci China Mater. 2021;64:1827\u201348. https:\/\/doi.org\/10.1007\/s40843-020-1627-4.","journal-title":"Sci China Mater"},{"key":"4314_CR186","doi-asserted-by":"publisher","unstructured":"Kelloff GJ, Hawk ET, Sigman CC, editors. Cancer Chemoprevention: Volume 2: Strategies for Cancer Chemoprevention. Springer Science & Business Media; 2008. https:\/\/doi.org\/10.5005\/jp\/books\/11166_22","DOI":"10.5005\/jp\/books\/11166_22"},{"issue":"8","key":"4314_CR187","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/carcin\/bgi372","volume":"27","author":"S Banerjee","year":"2006","unstructured":"Banerjee S, Panda CK, Das S. Clove (Syzygium aromaticum L.), a potential chemopreventive agent for lung cancer. Carcinogenesis. 2006;27(8):1645\u201354. https:\/\/doi.org\/10.1093\/carcin\/bgi372.","journal-title":"Carcinogenesis"},{"key":"4314_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcab.2019.101425","volume":"22","author":"I Chakraborty","year":"2019","unstructured":"Chakraborty I, Sen IK, Mondal S, Rout D, Bhanja SK, Maity GN, et al. Bioactive polysaccharides from natural sources: A review on the antitumor and immunomodulating activities. Biocatal Agric Biotechnol. 2019;22:101425. https:\/\/doi.org\/10.1016\/j.bcab.2019.101425.","journal-title":"Biocatal Agric Biotechnol"},{"issue":"5","key":"4314_CR189","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jtcme.2024.03.002","volume":"14","author":"MA Liss","year":"2024","unstructured":"Liss MA, Dursun F, Hackman GL, Gadallah MI, Saha A, Friedman CA, et al. Phase 1 clinical trial evaluating safety, bioavailability, and gut microbiome with a combination of curcumin and ursolic acid in lipid enhanced capsules. J Tradit Complement Med. 2024;14(5):558\u201367. https:\/\/doi.org\/10.1016\/j.jtcme.2024.03.002.","journal-title":"J Tradit Complement Med"},{"key":"4314_CR190","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11101-024-09955-7","volume":"24","author":"SF Vieira","year":"2025","unstructured":"Vieira SF, Reis RL, Ferreira H, Neves NM. Plant-derived bioactive compounds as key players in the modulation of immune-related conditions. Phytochem Rev. 2025;24:343\u2013460. https:\/\/doi.org\/10.1007\/s11101-024-09955-7.","journal-title":"Phytochem Rev"},{"issue":"3","key":"4314_CR191","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4274\/ejbh.galenos.2024.2024-3-8","volume":"20","author":"G Rais","year":"2024","unstructured":"Rais G, Mokfi R, Boutaggount F, Maskrout M, Bennour S, Senoussi C, et al. Assessment of the predictive role of Ki-67 in breast cancer patients\u2019 responses to neoadjuvant chemotherapy. Eur J Breast Health. 2024;20(3):199\u2013206. https:\/\/doi.org\/10.4274\/ejbh.galenos.2024.2024-3-8.","journal-title":"Eur J Breast Health"},{"issue":"3","key":"4314_CR192","doi-asserted-by":"publisher","first-page":"426","DOI":"10.4103\/ijc.IJC_60_21","volume":"61","author":"J Deng","year":"2024","unstructured":"Deng J, Luo L, Ren W, Zhang J, Hu C, Zhao K. Prognostic value of proliferation markers Ki-67 and PCNA in esophageal squamous cell carcinoma. Indian J Cancer. 2024;61(3):426\u201333. https:\/\/doi.org\/10.4103\/ijc.IJC_60_21.","journal-title":"Indian J Cancer"},{"key":"4314_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101432","volume":"58","author":"MA Toli","year":"2025","unstructured":"Toli MA, Liu X, Massa D, Lando S, Boman C, Tsiknakis N, et al. Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study. Lancet Reg Health Eur. 2025;58:101432. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101432.","journal-title":"Lancet Reg Health Eur"},{"key":"4314_CR194","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1303335","volume":"14","author":"X Wang","year":"2024","unstructured":"Wang X, Wang L, Lin H, Zhu Y, Huang D, Lai M, et al. Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy. Front Oncol. 2024;14:1303335. https:\/\/doi.org\/10.3389\/fonc.2024.1303335.","journal-title":"Front Oncol"},{"issue":"1","key":"4314_CR195","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00876-y","volume":"9","author":"A Bartolomucci","year":"2025","unstructured":"Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, Kaorey N, Nadeau A, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. npj Precis Oncol. 2025;9(1):84. https:\/\/doi.org\/10.1038\/s41698-025-00876-y.","journal-title":"npj Precis Oncol"},{"issue":"16","key":"4314_CR196","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25168703","volume":"25","author":"J Chung","year":"2024","unstructured":"Chung J, Xiao S, Gao Y, Soung YH. Recent technologies towards diagnostic and therapeutic applications of circulating nucleic acids in colorectal cancers. Int J Mol Sci. 2024;25(16):8703. https:\/\/doi.org\/10.3390\/ijms25168703.","journal-title":"Int J Mol Sci"},{"issue":"13","key":"4314_CR197","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132432","volume":"16","author":"K Turabi","year":"2024","unstructured":"Turabi K, Klute K, Radhakrishnan P. Decoding the dynamics of circulating tumor DNA in liquid biopsies. Cancers. 2024;16(13):2432. https:\/\/doi.org\/10.3390\/cancers16132432.","journal-title":"Cancers"},{"issue":"6","key":"4314_CR198","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061213","volume":"16","author":"P Salu","year":"2024","unstructured":"Salu P, Reindl KM. Advancements in circulating tumor cell research: bridging biology and clinical applications. Cancers. 2024;16(6):1213. https:\/\/doi.org\/10.3390\/cancers16061213.","journal-title":"Cancers"},{"issue":"7","key":"4314_CR199","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071377","volume":"16","author":"TA Allen","year":"2024","unstructured":"Allen TA. The role of circulating tumor cells as a liquid biopsy for cancer: advances, biology, technical challenges, and clinical relevance. Cancers (Basel). 2024;16(7):1377. https:\/\/doi.org\/10.3390\/cancers16071377. (Published 2024 Mar 31).","journal-title":"Cancers (Basel)"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04314-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04314-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04314-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T03:22:05Z","timestamp":1787455325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04314-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":199,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4314"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04314-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the preparation of this work, the author(s) used perplexity to rectify grammatical errors. After using this tool\/service, the author(s) reviewed and edited the content as needed and took full responsibility for the content of the published article.","order":1,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the manuscript preparation process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For writing this manuscript, no animals were used, and no human information was included directly. All the data were collected from open-access journal sources, and subsequent citations were provided accordingly.","order":2,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}